2x SYBR Green qPCR Master Mix

2x SYBR Green qPCR Master Mix(Low ROX)

2x SYBR Green qPCR Master Mix(High ROX)

Protein A/G免疫沉淀磁珠

Anti-Flag免疫磁珠

Anti-Flag亲和凝胶

Anti-Myc免疫磁珠

Anti-HA免疫磁珠

Poly FlAG多肽

蛋白酶抑制剂Cocktail

蛋白酶抑制剂Cocktail(DMSO储液)

磷酸酶抑制剂Cocktail

Cell Counting Kit-8 (CCK-8)

鼠尾直接PCR试剂盒(快速基因型鉴定)

小鼠CD3 ⁺ T细胞分选试剂盒

小鼠CD4 ⁺ T细胞分选试剂盒

小鼠CD8 ⁺ T细胞分选试剂盒

0.16 μM Neuroprotective activity in mouse MN9D cells assessed as blocking of TNF-alpha associated toxicity at 0.16 uM after 72 hrs by Trypan blue staining. 25050165 0.16 μM Neuroprotective activity in mouse MN9D cells assessed as stimulation of BDNF expression at 0.16 uM after 24 hrs 25050165 30 to 120 mins Induction of PP2A catalytic subunit activity in rat PC12 cells assessed as phosphate level at 5 uM measured 30 to 120 mins. 25050165 10 mg/kg 20 days Antitumor activity against human MGC803 cells xenografted in nude mouse assessed as inhibition of tumor growth at 10 mg/kg for 20 days 21456524 10 uM 3 hrs Cytotoxicity against mouse FL5.12 cells assessed as vacuole formation at 10 uM after 3 hrs by fluorescence microscopic analysis 30292898 2.5 uM 3 hrs Cytotoxicity against mouse FL5.12 cells assessed as vacuole formation at 2.5 uM after 3 hrs by fluorescence microscopic analysis 30292898 Induction of PP2A catalytic subunit activity in mouse MN9D cells assessed as phosphate level at 5 uM 25050165 Inhibition of human recombinant S1PL (62 to 568) expressed in Sf9 insect cells using S1P as substrate after 1 hr 24809814 Cytotoxicity against BCR-ABL fusion protein 190 expressing mouse bone marrow cells after 72 hrs by vital dye exclusion/flow cytometric analysis, IC50=3.3 μM. 24273632 Cytotoxicity against Ph-negative human BLIN-1 cells after 72 hrs by vital dye exclusion/flow cytometric analysis, IC50=5.5 μM. 24273632 Cytotoxicity against Ph-positive human BV173 cells after 72 hrs by vital dye exclusion/flow cytometric analysis, IC50=6.3 μM. 24273632 Cytotoxicity against human DU145 cells after 72 hrs by vital dye exclusion/flow cytometric analysis, IC50=6.5 μM. 24273632 Cytotoxicity against Ph-positive human SUP-B15 cells after 72 hrs by vital dye exclusion/flow cytometric analysis, IC50=6.8 μM. 24273632 Cytotoxicity against Ph-negative human CCRF-CEM cells after 72 hrs by vital dye exclusion/flow cytometric analysis, IC50=6.8 μM. 24273632 Cytotoxicity against Ph-negative human NALM6 cells after 72 hrs by vital dye exclusion/flow cytometric analysis, IC50=9.6 μM. 24273632 Cytotoxicity against human PC3 cells after 72 hrs by vital dye exclusion/flow cytometric analysis, IC50=9.8 μM. 24273632 18 hrs Reversal of inhibition of mitochondrial function in human Jurkat cells after 18 hrs in presence of Z-VAD-fmk 17400555 96 hrs Immunosuppressive activity in BALB/c/C57BL/6 mouse T cells assessed as inhibition of alloantigen-induced cell proliferation after 96 hrs by measuring [3H]thymidine uptake by mixed lymphocyte reaction assay, IC50=0.0061μM. 21456524 78 hrs Antiproliferative activity against human SK-BR-3 cells assessed as growth inhibition after 78 hrs by WST-1 assay, IC50=5μM. 21456524 78 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 78 hrs by WST-1 assay, IC50=5μM. 21456524 78 hrs Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 78 hrs by WST-1 assay, IC50=5μM. 21456524 78 hrs Antiproliferative activity against human SW620 cells assessed as growth inhibition after 78 hrs by WST-1 assay, IC50=5μM. 21456524 78 hrs Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 78 hrs by WST-1 assay, IC50=5μM. 21456524 78 hrs Antiproliferative activity human LNCAP-AI cells assessed as growth inhibition after 78 hrs by WST-1 assay, IC50=5μM. 21456524 18 hrs Agonist activity at human S1P1 receptor expressed in EDG1-bla U2OS cells incubated for 18 hrs prior to GenBlazer substrate addition by beta-arrestin recruitment assay, EC50=0.0072μM. 26687487 48 hrs Cytotoxicity against mouse FL5.12A cells after 48 hrs by DAPI staining-based flow cytometric analysis, IC50=2.4μM. 27475534 24 hrs Cytotoxicity against human SH-SY5Y cells measured after 24 hrs by crystal-violet staining based assay, EC10=0.54μM. 27913115 24 hrs Cytotoxicity against human SK-N-SH cells measured after 24 hrs by crystal-violet staining based assay, EC10=0.55μM. 27913115 24 hrs Cytotoxicity against human U118MG cells measured after 24 hrs by crystal-violet staining based assay, EC10=0.61μM. 27913115 18 hrs Agonist activity at sphingosine-1-phosphate receptor (unknown origin) expressed in HEK293 cells assessed as increase in cAMP level at EC10 after 18 hrs by CRE-responsive renilla luciferase reporter gene assay 27913115 48 hrs Cytotoxicity against mouse FL5.12 cells after 48 hrs by DAPI or propidium iodide staining-based flow cytometric analysis, IC50=2.1μM. 30292898 Agonist activity at human S1P1 receptor expressed in human U2OS cells co-expressing eGFP assessed as receptor internalization into cytoplasm using Hoechst dye staining, EC50=0.002 μM. 22104144 Displacement of [33P]sphingosine 1 phosphate from human S1P1 receptor expressed in CHO cells, IC50=0.84μM. 15615513 Displacement of [33P]sphingosine 1 phosphate from human S1P5 receptor expressed in CHO cells, IC50=2.1μM. 15615513 Agonist activity at sphingosine-1-phosphate receptor in human SH-SY5Y cells assessed as increase in cAMP level at EC10 by direct immunoassay 27913115 Agonist activity at sphingosine-1-phosphate receptor in human U118MG cells assessed as increase in cAMP level at EC10 by direct immunoassay 27913115 Agonist activity at sphingosine-1-phosphate receptor human SK-N-SH cells assessed as increase in cAMP level at EC10 by direct immunoassay 27913115 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells 29435139 qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139 Agonist activity at human S1P3 receptor expressed in CHO cells assessed as increase in calcium flux by aequorin-derived luminescence assay, EC50=2.51189μM. ChEMBL Agonist activity at human S1P5 receptor expressed in CHO cells assessed as increase in calcium flux by aequorin-derived luminescence assay, EC50=3.16228μM. ChEMBL 体外研究活性

S1P 作用于K562细胞，抑制NK细胞裂解。多种浓度 FTY720可逆转S1P的抑制作用，IC50为173 nM。此外, 10 nM FTY720 单独温育时，对共刺激分子的表达没有任何影响。通过比较S1P的作用效果与S1P和 FTY720联合作用效果，FTY720 可逆转S1P诱导的 HLA-I 表达提高，同时对于细胞百分数和MFI。 ^[1] 培养基和高剂量 FTY720-P也增强 TGF-β1水平。在高剂量FTY720-P 组别中可上调TGF-β1 和 Foxp3 mRNA的表达。在培养基和高剂量FTY720-P 组别中的效应 T(Teff)细胞增殖受抑制，Treg/Teff细胞比率为1:1。比率为1:1时,高剂量 FTY720 组别中的Teff细胞也受抑制。 ^[2]

未成熟的 DCs原封不动，或与 2 μM S1P, 10 nM FTY720, 10 nM SEW2871或S1P 与这些药剂的联和温育4小时。使用1 μg/mL LPS作为对照。冲洗细胞，在96孔板(v-型底,每孔 2 × 10 ⁵ 个细胞)中温育,再次冲洗，再悬浮在含0.1%叠氮化钠的 PBS buffer 中。使用1 μg/mL FITC标记的小鼠抗人CD80, CD83, CD86, HLA-class I, HLA-DR, 1 μg/mL HLA-E标记, 使用1 μg/mL FITC标记的小鼠 IgG 作为对照。细胞冲洗两次，在流式细胞仪中检测。根据同型对照 FITC标记的小鼠IgG进行标记。使用多种NK 细胞激活受体的抗体对NK细胞进行染色，或使细胞原封不动或与 2 μM S1P 温育4小时，冲洗，使用1 μg/mL PE标记的小鼠抗人NKp30 (CD337), NKp44 (CD336), NKG2D (CD314),在4 ^o C下染色45分钟，使用1 μg/mL PE标记的小鼠IgG1作为对照。也使用1 μg/mL FITC标记的抗-杀伤抑制性受体(KIR)/CD158 抗体（识别KIR2DL2, KIR2DL3, KIR2DS2 和KIR2DS4）对NK细胞进行染色，使用FITC标记的小鼠 IgG作为对照。冲洗细胞两次，在流式细胞仪中检测。

April 30 2017 Phase 4 NCT02575365 Terminated February 16 2016 Phase 4

[1] Rolin J, et al. Cancer Immunol Immunother. 2010, 59(4), 575-586.

[2] Liu Y, et al. Int J Mol Med. 2012, 30(1), 211-219.

[3] Wallington-Beddoe CT, et al. PLoS One. 2012, 7(5), e36429.

[4] Nikolova Z, et al. Transpl Immunol. 2001, 8(4), 267-277.

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL， 注 ：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法： 取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入 μL Tween 80，混匀澄清后加入 μL ddH ₂ O，混匀澄清。

体内配方配制方法： 取 μL DMSO母液，加入 μL Corn oil，混匀澄清。

注意： 1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。 在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱 [email protected] ，直接联系到我们。我们会在24小时内尽快联系您。

如果有其他问题，请给我们留言。

* 必填项

请输入您的姓名 请输入您的邮箱地址 请输入一个有效的邮箱地址 * 留言内容 请写点东西给我们

全国免费电话: 400-668-6834    技术支持电话: 400-168-6834

订购及询单: [email protected] 技术支持: [email protected]

物流及运输信息: [email protected] 合作: [email protected]

Email: [email protected]